Lixisenatide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Lixisenatide: From Type 2 Diabetes Mellitus to Opsismodysplasia
One-Sentence Summary
Lixisenatide is a GLP-1 receptor agonist established for type 2 diabetes mellitus (formal regulatory indication text not available in this jurisdiction, where the drug is currently unmarketed). The TxGNN model’s top prediction is Opsismodysplasia, a rare skeletal dysplasia, but this is supported by 0 clinical trials and 0 publications, and the model’s own rationale flags the link as a knowledge-graph proximity artifact rather than a mechanistic signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from regulatory licenses (drug not marketed in this jurisdiction); known class use is Type 2 Diabetes Mellitus |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 97.56% |
| Evidence Level | L5 (model prediction only) |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on known information, Lixisenatide is a GLP-1 receptor agonist that increases insulin secretion and reduces insulin resistance, with established use in type 2 diabetes mellitus.
Opsismodysplasia is a rare skeletal dysplasia caused by INPPL1 gene mutations. There is no known physiological connection between GLP-1 receptor signaling and this bone development pathway. The evidence pack’s own repurposing rationale explicitly states the high TxGNN score likely reflects graph-proximity clustering rather than a mechanistic inference, and no preclinical or clinical data exist to substantiate the link.
Across all 10 TxGNN-ranked candidates for this drug, only one (rank 6, pancreatic agenesis) has any supporting literature, and even that single preclinical study (a tumor-cachexia rat model) addresses a different biological question than the predicted indication. This pattern — high model scores with consistently absent or mismatched external evidence — indicates the current signal is exploratory only and not yet actionable.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for the top-ranked prediction (Opsismodysplasia).
Note: One tangentially related preclinical study exists for a lower-ranked candidate (rank 6, pancreatic agenesis) — Quintilhano et al., 2021, PMID 32911572, Cell Biochemistry and Function — examining lixisenatide’s effect on cachexia in tumor-bearing rats. This does not directly support pancreatic agenesis (a congenital PDX1/PTF1A-related disorder) and is not evidence for the top-ranked indication.
EU Market Information
Not currently marketed in this jurisdiction — 0 marketing authorizations on record.
Safety Considerations
Please refer to the SmPC for safety information.
Note: TFDA/label warnings and contraindications data are marked as a Blocking-severity gap (DG001) — this evaluation cannot proceed past initial safety screening (S1) without this data.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction (Opsismodysplasia) has no clinical, preclinical, or literature support, and the mechanistic rationale is explicitly assessed as non-biological (graph-proximity artifact). Combined with a Blocking data gap on safety labeling and a High-severity gap on mechanism of action, there is insufficient basis to advance this candidate.
To proceed, the following is needed:
- TFDA/regulatory label warnings and contraindications (Blocking gap, DG001)
- Confirmed mechanism of action data via DrugBank or equivalent source (DG002)
- Any preclinical or in vitro evidence directly linking GLP-1 receptor activity to skeletal/connective tissue pathways relevant to opsismodysplasia
- Re-screening of lower-ranked candidates (e.g., lipodystrophy-related indications) where a plausible metabolic mechanism exists, even though direct evidence is currently absent
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.